Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0081452 |
| Name | large B-cell lymphoma |
| Definition | A B-cell lymphoma that is characterized by large lymphoid cells of the B-cell lineage that by definition form sheets or clusters. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma large B-cell lymphoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03696784 | Phase I | Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK | Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | Active, not recruiting | USA | 0 |
| NCT03960840 | Phase I | Ibrutinib + YTB323 YTB323 | CD19-specific CAR-T Cells in CLL/SLL and DLBCL | Active, not recruiting | USA | ITA | FRA | ESP | DEU | AUT | AUS | 1 |
| NCT04002947 | Phase II | Acalabrutinib + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
| NCT04231877 | Phase I | Cyclophosphamide + Doxorubicin + Etoposide + Glofitamab-gxbm + Polatuzumab vedotin-piiq + Prednisone + Rituximab | Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma | Recruiting | USA | 0 |
| NCT04970901 | Phase I | Obinutuzumab Loncastuximab tesirine-lpyl + Mosunetuzumab-axgb Loncastuximab tesirine-lpyl + Polatuzumab vedotin-piiq Glofitamab-gxbm + Loncastuximab tesirine-lpyl | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | Recruiting | USA | ITA | GBR | ESP | CZE | BEL | 0 |
| NCT05412290 | Phase I | Mosunetuzumab-axgb | Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | Recruiting | USA | 0 |
| NCT05421663 | Phase Ib/II | C-CAR039 | A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | NLD | GBR | ESP | DNK | CAN | AUS | 1 |
| NCT05852717 | Phase II | Cisplatin + Dexamethasone + Epcoritamab-bysp + Gemcitabine | Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
| NCT06045910 | Phase Ib/II | ALETA-001 | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies | Recruiting | GBR | 0 |
| NCT06050694 | Phase II | Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab | Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) (GRAIL) | Recruiting | CAN | 0 |
| NCT06071871 | Phase II | Glofitamab-gxbm + Obinutuzumab + Polatuzumab vedotin-piiq | A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma (PORTAL) | Recruiting | GBR | 0 |
| NCT06167785 | Phase II | Zanubrutinib Tislelizumab + Zanubrutinib Tislelizumab | A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T (ZeTA) | Recruiting | CAN | 0 |
| NCT06248086 | Phase I | ASP101G + ASP2802 | A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas | Terminated | AUS | 0 |
| NCT06340737 | Phase I | Anti-CD22 CAR T cells | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | Recruiting | USA | 0 |
| NCT06414148 | Phase II | Epcoritamab-bysp + Lenalidomide + Rituximab Epcoritamab-bysp | MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART) | Recruiting | AUS | 0 |
| NCT06486051 | Phase II | Cyclophosphamide + Fludarabine WZTL-002 | A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma (ENABLE-2) | Recruiting | NZL | 0 |
| NCT06500273 | Phase II | ALLO-501A Cyclophosphamide + Fludarabine | Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL (ALPHA3) | Recruiting | USA | CAN | 0 |
| NCT06526793 | Phase II | TNB-486 | AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL (SOUNDTRACK-B) | Recruiting | USA | SWE | ITA | GBR | FRA | ESP | DNK | DEU | CAN | BRA | AUS | 5 |
| NCT06528301 | Phase I | UB-VV111 Sirolimus + UB-VV111 | A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies | Recruiting | USA | AUS | 0 |
| NCT06536049 | Phase Ib/II | Epcoritamab-bysp + Ibrutinib | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
| NCT06542250 | Phase Ib/II | AZD5492 | A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. (TITANium) | Recruiting | USA | ITA | FRA | ESP | DNK | DEU | CAN | AUS | 2 |
| NCT06564038 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + TNB-486 + Vincristine Sulfate Acalabrutinib + TNB-486 TNB-486 | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (Soundtrack-E) | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | DEU | CZE | AUS | 4 |
| NCT06593145 | Phase I | Tarcidomgen kimleucel | CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms (CARLA) | Recruiting | POL | 0 |
| NCT06594939 | Phase II | Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Prednisone Pegfilgrastim Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Prednisone | Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma | Not yet recruiting | USA | 0 |
| NCT06723457 | Phase II | Epcoritamab-bysp + Lenalidomide | Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma | Recruiting | USA | 0 |
| NCT06730542 | Phase I | Cyclophosphamide + Doxorubicin + Methotrexate + Polatuzumab vedotin-piiq + Prednisone + Rituximab + Zanubrutinib | Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in Patients with Secondary CNS Lymphoma | Recruiting | USA | 0 |
| NCT06760156 | Phase II | Lenalidomide + Tafasitamab-cxix | Phase 2 Study of Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym | Recruiting | USA | 0 |
| NCT06784726 | Phase II | Odronextamab | Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T | Recruiting | USA | 0 |
| NCT06811272 | Phase II | Epcoritamab-bysp Dexamethasone + Epcoritamab-bysp | Outpatient Epcoritamab As 2L in NTE R/R DLBCL | Recruiting | USA | 0 |
| NCT06834373 | Phase II | CC-99282 + Rituximab | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | Recruiting | USA | 0 |
| NCT06870487 | Phase I | PF-08046032 PF-06801591 + PF-08046032 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers | Active, not recruiting | USA | ESP | 0 |
| NCT06905509 | Phase II | Cytarabine + Dexamethasone + Epcoritamab-bysp + Oxaliplatin + Rituximab Epcoritamab-bysp + Gemcitabine + Oxaliplatin Carboplatin + Cytarabine + Dexamethasone + Epcoritamab-bysp + Rituximab Carboplatin + Epcoritamab-bysp + Etoposide + Ifosfamide + Rituximab | Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
| NCT06919939 | Phase II | Epcoritamab-bysp + Loncastuximab tesirine-lpyl | Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma (EPCOR+LONCA) | Not yet recruiting | USA | 0 |
| NCT07052305 | Phase I | NT-I7 | NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Yescarta (Axicabtagene Ciloleucel) or Post-Breyanzi (Lisocabtagene Maraleucel) in Subjects With Relapsed/Refractory Large B-cell Lymphoma | Not yet recruiting | USA | 0 |
| NCT07097363 | Phase II | Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Etoposide + Prednisone + Rituximab | Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma | Not yet recruiting | USA | 0 |
| NCT07098364 | Phase Ib/II | Lisocabtagene maraleucel + ST-067 | ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma | Recruiting | USA | 0 |
| NCT07108868 | Phase I | MB-CART2219.1 | A Phase I Dose Finding Study of MB-CART2219.1 | Recruiting | DEU | 0 |
| NCT07123454 | Phase Ib/II | AZD4512 | A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (Lumi-NHL) | Recruiting | USA | ITA | GBR | AUS | 3 |
| NCT07126236 | Phase II | Epcoritamab-bysp Epcoritamab-bysp + Lenalidomide + Tafasitamab-cxix | Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma (REPIFIR) | Recruiting | ESP | 0 |
| NCT07215585 | Phase III | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + TNB-486 + Vincristine Sulfate | AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (SOUNDTRACK-D2) | Recruiting | TUR | POL | GBR | CAN | BRA | BEL | AUS | 4 |
| NCT07226843 | Phase I | LY4584180 + Rituximab LY4584180 | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | Not yet recruiting | USA | 0 |